Login
$NSPR
$0.60 -$0.04 (6.85%) Live

$NSPR SEC Filings

Filed On Filing
16 Nov 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Date of report (Date of earliest event reported): November 13, 2026

16 Nov 2026 424B5
12 Nov 2026 424B5
12 Nov 2026 8-K: Results of Operations and Financial Condition; Other Events

- Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market -

12 Nov 2026 8-K: Regulation FD Disclosure; Other Events

- Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR procedures annually –

23 Sep 2026 Form 4: Berman Michael, Director

Disposed of 30,625 Series J Warrant (right to buy) (Other Transaction) · Acquired 30,625 Series J Warrant (right to buy) (Other Transaction) · Disposed of 61,248 Series K Warrant (right to buy) (Other Transaction) · 1 more

23 Sep 2026 Form 4: Roubin Gary S, Director

Disposed of 15,313 Series J Warrant (right to buy) (Other Transaction) · Acquired 15,313 Series J Warrant (right to buy) (Other Transaction) · Disposed of 30,624 Series K Warrant (right to buy) (Other Transaction) · 1 more

23 Sep 2026 Form 4: Stuka Paul, Director

Disposed of 43,750 Series J Warrant (right to buy) (Other Transaction) · Acquired 43,750 Series J Warrant (right to buy) (Other Transaction) · Disposed of 87,500 Series K Warrant (right to buy) (Other Transaction) · 1 more

21 Sep 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

THIS SERIES J COMMON STOCK PURCHASE WARRANT AMENDMENT (this “Amendment”) is entered into as of September 21, 2026, by and between InspireMD, Inc., a Delaware corporation (the “Company”), and the holder identified on the signature page he...

17 Aug 2026 8-K: Results of Operations and Financial Condition

- Company to host investor conference call today, August 17th, at 8:30am EDT -

14 Aug 2026 10-Q
29 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

On July 23, 2026, InspireMD, Inc. (the “Company”) provided notice to Shane Gleason, the Company’s Chief Commercial Officer, that his position has been eliminated. His last day of employment with the Company will be July 31, 2026.

23 Jul 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On July 17, 2026, InspireMD, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum b...

02 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

On June 26, 2026, Mr. Raymond W. Cohen, a Class III member of the board of directors (the “Board”) of InspireMD, Inc. (the “Company”), a member of the Audit Committee of the Board and a member of the Compensation Committee of the Board, ...

11 Jun 2026 8-K: Regulation FD Disclosure

InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures

03 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

InspireMD, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify that:

29 May 2026 Form 4: Stuka Paul, Director

Bought 20,000 shares ($17.5K)

22 May 2026 8-K: Departure/Election of Directors or Officers; Compensation

On May 20, 2026, Mr. Paul Stuka notified InspireMD, Inc. (the “Company”) of his decision to not seek reelection as a Class I director of the Board of Directors of the Company (the “Board”) at the Company’s 2027 Annual Meeting of Stockhol...

21 May 2026 Form 4: Gleason Shane Thomas, Chief Commercial Officer

Sold 3,858 shares ($10.5K) · Sold 2,476 shares ($6.46K) · Sold 3,660 shares ($9K) · 11 more

15 May 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support